原始来源记录
决策级顶线结果
COMPASS Pathways 公布 COMP360 治疗 TRD 的 COMP006 3 期积极数据
COMP006 是第二项关键 3 期试验，主要终点在第 6 周达到高度统计学显著的 MADRS 改善（P<0.001），并在 26 周内持续分离。COMP005 与 COMP006 两项试验在超过 1,000 名 TRD 患者中提供了持续且持久的疗效数据，支持正在进行的滚动 NDA 提交，预计将于 2026 年第四季度完成。
关键事实
来源摘录
EX-99.1 2 a8-kdated7july2026ex991.htm EX-99.1 a8-kdated7july2026ex991 © Compass Pathways | 1 Compass Pathways Phase 3 COMP006 data review July 7, 2026 © Compass Pathways | 2 Cautionary Note Regarding Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, you can identify forward-looking statements by terms such as “believe,” “continue,” “could,” “estimate，” “expect，” “may，” “might，” “plan，” “potential，” “project，” “target，” “will，” “would，” or the negative of these terms, and similar expressions intended to identify forward-looking statements. However, not all forward-looking statements contain these identifying words. These forward-looking statements includ